{
    "nct_id": "NCT03675451",
    "official_title": "PSMA Imaging of Localized Prostate Cancer",
    "inclusion_criteria": "* Patients must have histologically or cytologically confirmed localized prostate cancer that are scheduled to undergo radical prostatectomy.\n* Age >18 years.\n* Patients must have laboratory values consistent with eligibility to undergo a radical prostatectomy:\n\n  * creatinine less than or equal to 1.5 X upper limit of normal\n  * creatinine clearance > 60 mL/min\n* The effects of 89Zr-Df-IAB2M on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her male partner is participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or investigational therapy between the time of conventional imaging, 89Zr-Df-IAB2M PET/CT and the surgical resection used for the study evaluation.\n* Transrectal prostate biopsy performed less than four weeks prior to 89Zr-Df-IAB2M administration.\n* Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "miscellaneous_criteria": ""
}